GOLPH3 Antibody [L14M1] Datasheet

Biological Description

Specificity	GOLPH3 Antibody [L14M1] detects endogenous levels of total GOLPH3 protein.
Background	GOLPH3 (Golgi phosphoprotein 3; also known as GPP34, GMx33, MIDAS, VPS74 ortholog) is an evolutionarily conserved phosphatidylinositol‑4‑phosphate–binding peripheral membrane protein of the trans‑Golgi that functions as a key organizer of Golgi architecture, vesicle formation, and growth signaling and is recognized as a first‑in‑class Golgi oncoprotein. The protein has a small N‑terminal region and a curved β‑sheet–rich globular C‑terminal domain that forms a dimer and presents a defined binding pocket for phosphatidylinositol‑4‑phosphate, allowing selective association with PI4P‑rich trans‑Golgi membranes, while separate surfaces bind the unconventional myosin MYO18A and components of COPI and glycosyltransferase cytosolic tails. By simultaneously engaging PI4P-containing Golgi membranes and MYO18A, GOLPH3 links the Golgi to the actin cytoskeleton and generates a tensile force parallel to the cis–trans axis of the Golgi stack, a mechanical arrangement that flattens Golgi cisternae and promotes efficient budding of tubules and vesicles required for anterograde trafficking toward the plasma membrane and for intra‑Golgi enzyme recycling. GOLPH3 also acts as a glyco‑enzyme adaptor that binds the cytosolic tails of specific glycosyltransferases and retains or recycles them within the Golgi, reducing their escape to endosomes and lysosomes and thereby stabilizing the composition and localization of glycosylation enzymes, which shapes glycan profiles on secreted and cell-surface proteins and influences receptor function and extracellular matrix interactions. These trafficking and enzyme‑sorting roles integrate with signaling pathways because GOLPH3-dependent vesicle formation and receptor recycling modulate the abundance and activity of growth factor receptors and other signaling cargoes, and genetic and functional analyses show that GOLPH3 enhances mammalian target of rapamycin (mTOR) signaling and controls organ growth through direct or indirect interactions with TOR pathway proteins, linking Golgi output to cell growth, proliferation, and survival. The GOLPH3 pathway also responds to genotoxic stress, with DNA damage activating GOLPH3‑MYO18A–dependent Golgi dispersal and altering secretion patterns, which connects nuclear DNA damage responses to Golgi morphology and secretory adaptation and supports survival of damaged cells. GOLPH3 is frequently amplified and overexpressed in a broad range of solid tumors, including melanoma, breast, lung, prostate, and glioma, and increased GOLPH3 levels associate with higher proliferation rates, enhanced migration, metastatic behavior, resistance to chemoradiotherapy, and poor prognosis, establishing GOLPH3 as a clinically relevant oncoprotein positioned at the intersection of vesicle trafficking, glycosylation control, cytoskeletal coupling, and mTOR-driven growth signaling.

Specificity

GOLPH3 Antibody [L14M1] detects endogenous levels of total GOLPH3 protein.

Background

GOLPH3 (Golgi phosphoprotein 3; also known as GPP34, GMx33, MIDAS, VPS74 ortholog) is an evolutionarily conserved phosphatidylinositol‑4‑phosphate–binding peripheral membrane protein of the trans‑Golgi that functions as a key organizer of Golgi architecture, vesicle formation, and growth signaling and is recognized as a first‑in‑class Golgi oncoprotein. The protein has a small N‑terminal region and a curved β‑sheet–rich globular C‑terminal domain that forms a dimer and presents a defined binding pocket for phosphatidylinositol‑4‑phosphate, allowing selective association with PI4P‑rich trans‑Golgi membranes, while separate surfaces bind the unconventional myosin MYO18A and components of COPI and glycosyltransferase cytosolic tails. By simultaneously engaging PI4P-containing Golgi membranes and MYO18A, GOLPH3 links the Golgi to the actin cytoskeleton and generates a tensile force parallel to the cis–trans axis of the Golgi stack, a mechanical arrangement that flattens Golgi cisternae and promotes efficient budding of tubules and vesicles required for anterograde trafficking toward the plasma membrane and for intra‑Golgi enzyme recycling. GOLPH3 also acts as a glyco‑enzyme adaptor that binds the cytosolic tails of specific glycosyltransferases and retains or recycles them within the Golgi, reducing their escape to endosomes and lysosomes and thereby stabilizing the composition and localization of glycosylation enzymes, which shapes glycan profiles on secreted and cell-surface proteins and influences receptor function and extracellular matrix interactions. These trafficking and enzyme‑sorting roles integrate with signaling pathways because GOLPH3-dependent vesicle formation and receptor recycling modulate the abundance and activity of growth factor receptors and other signaling cargoes, and genetic and functional analyses show that GOLPH3 enhances mammalian target of rapamycin (mTOR) signaling and controls organ growth through direct or indirect interactions with TOR pathway proteins, linking Golgi output to cell growth, proliferation, and survival. The GOLPH3 pathway also responds to genotoxic stress, with DNA damage activating GOLPH3‑MYO18A–dependent Golgi dispersal and altering secretion patterns, which connects nuclear DNA damage responses to Golgi morphology and secretory adaptation and supports survival of damaged cells. GOLPH3 is frequently amplified and overexpressed in a broad range of solid tumors, including melanoma, breast, lung, prostate, and glioma, and increased GOLPH3 levels associate with higher proliferation rates, enhanced migration, metastatic behavior, resistance to chemoradiotherapy, and poor prognosis, establishing GOLPH3 as a clinically relevant oncoprotein positioned at the intersection of vesicle trafficking, glycosylation control, cytoskeletal coupling, and mTOR-driven growth signaling.

Usage Information

Application

WB, IHC, IF

Dilution

WB	IHC	IF
1:5000-1:50000	1:500-1:2000	1:200-1:800

Reactivity

Mouse, Rat, Human

Source

Mouse Monoclonal Antibody

MW

34 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/25691054/
https://pubmed.ncbi.nlm.nih.gov/20354134/

GOLPH3 Antibody [L14M1]

Biological Description

Usage Information

References

Application Data